首页> Cancer medicine> Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.

Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Kelvin K W,Chan

第一单位： Cancer Care Ontario, Toronto, ON, Canada.;Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.;Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada.

作者： Kelvin K W,Chan ^[1] ; Helen,Guo ^[2] ; Sierra,Cheng ^[3] ; Jaclyn M,Beca ^[4] ; Ruby,Redmond-Misner ^[5] ; Wanrudee,Isaranuwatchai ^[4] ; Lucy,Qiao ^[2] ; Craig,Earle ^[6] ; Scott R,Berry ^[3] ; James J,Biagi ^[7] ; Stephen,Welch ^[8] ; Brandon M,Meyers ^[9] ; Nicole,Mittmann ^[2] ; Natalie,Coburn ^[3] ; Jessica,Arias ^[2] ; Deborah,Schwartz ^[2] ; Wei F,Dai ^[2] ; Scott,Gavura ^[2] ; Robin,McLeod ^[2] ; Erin D,Kennedy ^[10]

作者单位： Cancer Care Ontario, Toronto, ON, Canada.;Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.;Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada. ^[1] Cancer Care Ontario, Toronto, ON, Canada. ^[2] Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. ^[3] Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada.;Pharmacoeconomics Research Unit, Cancer Care Ontario, Toronto, ON, Canada. ^[4] Pharmacoeconomics Research Unit, Cancer Care Ontario, Toronto, ON, Canada. ^[5] Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.;Ontario Institute for Cancer Research, Toronto, ON, Canada. ^[6] Cancer Centre of Southeastern Ontario, Kingston, ON, Canada. ^[7] London Regional Cancer Program, London, ON, Canada. ^[8] Hamilton Health Sciences Centre, Hamilton, ON, Canada. ^[9] Cancer Care Ontario, Toronto, ON, Canada.;Mount Sinai Hospital, Toronto, ON, Canada. ^[10]

关键词 FOLFIRINOX gemcitabine outcomes pancreatic cancer real-world evidence